User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

8292

Interactions with Platform & by Email *

INTERACTIONS

1161

Unique # Participated *

PARTICIPANTS

249

Responses Validated *

VALIDATIONS

47

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
Quantitative Techniques & Analytics.....I-2
  
   Product Definitions and Scope of Study.....I-3
Cephalosporins.....I-3
Penicillins.....I-3
Fluoroquinolones.....I-3
Macrolides.....I-3
  
   Other Antibacterial Drugs.....I-4  
   Global Market Outlook.....II-1
Antibacterial Resistance – A Key Growth Dampener.....II-1
Antibacterial Resistance Costs High.....II-1
Patent Expiries Commoditize Antibacterials Market.....II-1
1$100
   Patent Expiries of Major Anti-Bacterial Drugs.....II-2
Generic Competition Intensifies.....II-2
Cephalosporins Dominate the Anti-bacterials Market.....II-2
1$100
   Table 1: Worldwide Market for Anti-Bacterials by Major Drug Class (2010): Percentage Share Breakdown for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others (includes corresponding Graph/Chart).....II-3
Macrolides and Fluoroquinolones to Grow At a Faster Rate.....II-3
Major Players and Key Brands.....II-3
1$350
   Table 2: Select Major Anti-Bacterial Drugs Worldwide (2008 & 2007): Value Sales in US$ Million for Levaquin/ Floxin, Zosyn/Tazocin, Zyvox, Augmentin, Merrem, Primaxin, Avelox/Avalox, Cravit, Zithromax/Zmax, Cipro/ Ciprobay, Rocephin (includes corresponding Graph/Chart).....II-4
United States Leads the Global Market, Other Regions to Exhibit Faster Growth.....II-4
1$350
   Injectables Gain Traction.....II-51$100
   Cephalosporins.....II-6
Select Major Cephalosporins Worldwide.....II-6
List of Select Cephalosporin Drugs by Generation.....II-6
1$100
   Drug Details of Select Cephalosporins.....II-7
Omnicef (Abbott Laboratories).....II-7
Rocephin (Roche).....II-7
Maxipime (Bristol Myers Squibb/Elan).....II-7
Zinnat (GlaxoSmithKline).....II-7
1$100
   Spectracef (Cornerstone BioPharma).....II-8
Fluoroquinolones.....II-8
Select Major Fluoroquinolones Worldwide.....II-8
1$100
   Drug Details of Select Fluoroquinolones.....II-9
Levaquin/Floxin/Cravit (Ortho-McNeil-Janssen/ Daiichi Sankyo).....II-9
Brand Names of Levofloxacin in Different Regions.....II-9
1$100
   Avelox (Bayer).....II-10
Ciprofloxacin (Various).....II-10
Macrolides.....II-10
1$100
   Drug Details of Select Macrolides.....II-11
Biaxin (Abbott).....II-11
Zmax (Pfizer Inc.).....II-11
1$100
   Penicillins.....II-12
Select Penicillins Worldwide.....II-12
1$100
   Table 3: Sales of Leading Penicillin Drugs in US$ Million (2006-2008) (includes corresponding Graph/Chart).....II-13
Drug Details of Select Penicillins.....II-13
Augmentin (GlaxoSmithKline).....II-13
Zosyn (Wyeth).....II-13
1$350
   Other Anti-bacterial Drugs.....II-14
Other Select Anti-bacterials Worldwide.....II-14
Details of Other Select Anti-bacterial Drugs Worldwide.....II-14
Zyvox (Pfizer).....II-14
1$100
   Cubicin (Cubist Pharmaceuticals).....II-15
Targocid (Sanofi-Aventis/Astellas).....II-15
Vancomycin (Eli Lilly).....II-15
1$100
   Carbapenems.....II-16
Faropenem (Replidyne).....II-16
Primaxin (Merck & Co.).....II-16
Merrem/Meronem (AstraZeneca).....II-16
2$125
   Bacterial Infections.....II-18
Types of Bacteria and Bacterial Infections.....II-18
1$100
   Overview of Select Bacterial Infections.....II-19
Pneumonia.....II-19
Intra-Abdominal Infections.....II-19
1$100
   Central Nervous System Infections.....II-20
Bloodstream Infections.....II-20
1$100
   Bone Infections.....II-21
Surgical Site Infections.....II-21
Urinary Tract Infections.....II-21
1$100
   Urethritis.....II-22
Hemorrhagic Cystitis.....II-22
Acute Pyelonephritis.....II-22
Anti-bacterial Drugs to Combat Against Bacteria.....II-22
Launch Year of Different Anti-Bacterial Drug Classes.....II-22
1$100
   Anti-bacterial Categorization.....II-23
Classification Based on Action Mechanism.....II-23
Classification Based on Method of Suppressing Bacterial Growth.....II-23
1$100
   Bactericidal Drugs.....II-24
Bacteriostatic Drugs.....II-24
Classification Based on Spectra of Activity.....II-24
Anti-Bacterial Drug Classes and their Uses.....II-24
Cephalosporins.....II-24
Treatment.....II-24
1$100
   Side Effects.....II-25
Penicillins.....II-25
History.....II-25
Types of Penicillins.....II-25
Side Effects.....II-25
1$100
   Fluoroquinolones.....II-26
Treatment.....II-26
Major Fluoroquinolones Worldwide, Along with Indications.....II-26
1$100
   Side Effects.....II-27
Macrolides.....II-27
1$100
   Select Macrolides and its Derivatives by Development Stage (As of 2008).....II-28
Treatment.....II-28
Side Effects.....II-28
Other Antibacterials.....II-28
Aminoglycosides.....II-28
1$100
   Treatment.....II-29
Aminoglycosides and Indications.....II-29
Side Effects.....II-29
Tetracyclines.....II-29
Treatment.....II-29
1$100
   Side Effects.....II-30
Sulfonamides.....II-30
Treatment.....II-30
Effects of the Drug.....II-30
1$100
   Mupirocin.....II-31
Carbepenems.....II-31
Aztreonam.....II-31
Glycopeptides.....II-31
Vancomycin.....II-31
1$100
   Teicoplanin.....II-32
Bacitracin.....II-32
Lincosamines.....II-32
Polymyxins.....II-32
Chloramphenicol.....II-32
Limitations of Antibacterial Therapy.....II-32
Bacterial Resistance.....II-32
1$100
   Antibacterial-Resistant Bacteria by Type.....II-33
Cross-resistance.....II-33
Phage Therapy, a Promising Approach for Bacterial Infections.....II-33
1$100
   Treatment and Application of Phase Therapy.....II-34
Phages for Antibiotic-Resistant Bacteria.....II-34
Companies Involved in Phage Therapy Research.....II-34
1$100
   Johnson & Johnson Receives Complete Response Letter for Ceftobiprole from US
  FDA.....II-35
Negative Opinion on Ceftobiprole by European CHMP.....II-35
Theravance and Astellas Obtains FDA Approval for VIBATIV™ for Treating Complicated Skin
  and Skin Structure Infections (cSSSI).....II-35
1$100
   Daiichi Sankyo Company Introduces Cravit® Formulations.....II-36
Forest Labs Announces Encouraging Phase III Results of Ceftaroline.....II-36
Cubist Pharma Initiates First-In-Human Clinical Trial with CB-183,315.....II-36
1$100
   Basilea Pharmaceutica Announces New Research Results for BAL30072 in Multi- Resistant
  Gram-Negative Bacteria.....II-37
Galderma Laboratories Launches Epiduo™ Gel for Acne Treatment.....II-37
Destiny Pharma Develops New Metallo-Porphyrin Anti-Bacterial Drug.....II-37
US FDA Asks Arpida to Secure Additional Data for Iclaprim.....II-37
1$100
   MiddleBrook Obtains FDA Approval for MOXATAG™.....II-38
MIT Scientists Develop a New Antibiotic, Rhodostreptomycin.....II-38
Watson Pharma Introduces Biaxin XL’s Generic Version.....II-38
Taisho Toyama Pharmaceutical Rolls Out Zosyn® to Treat Severe Bacterial
  Infections.....II-38
1$100
   GSK Launches ALTARGO® in the UK.....II-39
Daiichi Obtains Approval for Gracevit®.....II-39
New Research Backs LEVAQUIN Use in CAP Treatment in Concordance with
  Guidelines.....II-39
FDA Instructs Targanta to Conduct Additional Oritavancin Trials.....II-39
J&J’s Doribax Obtains FDA Approval for Urinary Tract and Intra-abdominal
  Infections.....II-39
1$100
   APL Receives FDA Approval for Cefpodoxime Proxetil.....II-40
Toyama Launches New Garenoxacin Quinolone Antibiotic.....II-40
Wockhardt to Introduce Cefprozil Tablets in the US.....II-40
MSD India Launches Invanza in India.....II-40
Macrolide Antibiotic Developed in the US.....II-40
1$100
   GSK Obtains EC Approval for Altargo® in Treating Skin Infections.....II-411$100
   Pfizer Indicts Teva for Zyvox Patent Infringement.....II-42
Beactica and Cubist Sign Agreement to Develop Advanced Anti-Bacterials.....II-42
Jiangchuan Pharmaceutical Forges Joint Venture with Sichuan Mingxin.....II-42
1$100
   Forest Laboratories Collaborates with AstraZeneca to Co-Develop Ceftaroline.....II-43
TB Alliance Enters into Multiple Deals for TB Drug Discovery.....II-43
Kemin Industries Acquires Amalyte Pharmaceuticals.....II-43
Forma Therapeutics Sign Deal with Cubist to Make Antibacterial Drugs.....II-43
Lee's Pharmaceutical Holdings Acquires Rights to Oral Antibacterial Drug.....II-43
1$100
   Anacor Pharmaceuticals Collaborates with TB Alliance.....II-44
Jiangchuan Pharmaceutical Forges Joint Venture with Sichuan Mingxin.....II-44
Evotec and Cubist Ink Research Pact for Fragment-Based Drug Discovery.....II-44
1$100
   Abbott Acquires Ibis Biosciences.....II-45
Elder and Strides on Expansion Mode.....II-45
Pfizer Inks Agreements with Claris Lifesciences and Aurobindo Pharma.....II-45
Akorn Signs Agreement with Eli Lilly and Company.....II-45
1$100
   NovaBay Inks Agreement with Medical University of Innsbruck.....II-46
Tibotec Collaborates with Global Alliance for TB Drug Development.....II-46
Sandoz Introduces Generic Maxipime®.....II-46
1$100
   Merck and Ranbaxy to Launch Anti-Bacterial and Anti-Fungal Drugs.....II-47
Wyeth Receives an Approvable Letter from US FDA for TYGACIL®.....II-47
Mylan Receives FDA Approval for Linezolid 600 mg Tablets.....II-47
Rottapharm/Madaus Obtains Clearance to Market ProQuin XR in Sweden.....II-47
MiddleBrook Obtains NDA Approval for MOXATAG™.....II-47
1$100
   ULL Establishes New Antibiotics Unit in Himachal Pradesh.....II-48
Biocat to Expand Presence in the Indian Market.....II-48
Novartis to Acquire Protez.....II-48
Orchid Signs Licensing Agreement with Merck.....II-48
1$100
   Forest and Novexel Sign Licensing Agreement.....II-49
Sanofi-aventis Collaborates with Novozymes.....II-49
AstraZeneca Acquires Arrow Therapeutics.....II-49
1$100
   Cubist Submits INDs for CB-182,804 and CB-183,315.....II-50
GlaxoSmithKline Enters into Strategic Alliance with Mpex Pharmaceuticals to Develop
  Novel Drugs to treat Bacterial Diseases.....II-50
Advanced Life Sciences and Wyeth Pharmaceuticals Sign Marketing Deal for
  Commercialization of Cethromycin in Asia Pacific.....II-50
GlaxoSmithKline Receives FDA Approval for Altabax.....II-50
1$100
   GSK and Anacor Team Up for Boron Chemistry-Based Antibiotics and Antivirals.....II-51
Cubist Pharmaceuticals Receives Health Canada Approval for CUBICIN®.....II-51
Cubist Obtains Approval to Market CUBICIN for Added Indications in EU.....II-51
Cubist Gains Approval for CUBICIN in Taiwan and South Korea.....II-51
1$100
   Cethromycin Achieves FDA’s Orphan Drug Designation.....II-52
GSK Receives Approval for ALTARGO® in Europe.....II-52
sanofi-aventis Updates Prescription Information for Ketek in the US.....II-52
1$100
   Abbott Laboratories (USA).....II-53
AstraZeneca PLC (UK).....II-53
Bayer HealthCare AG (Germany).....II-53
1$100
   Bristol-Myers Squibb Co. (USA).....II-54
Cubist Pharmaceuticals, Inc. (USA).....II-54
1$100
   Daiichi Sankyo Company, Ltd. (Japan).....II-55
GlaxoSmithKline Plc. (UK).....II-55
Johnson & Johnson (USA).....II-55
1$100
   Pfizer, Inc. (US).....II-56
Wyeth Pharmaceuticals, Inc. (US).....II-56
2$125
   Table 4: World Recent Past, Current & Future Analysis for Antibacterial Drugs by Geographic Region - US, Europe, Asia-Pacific (Inc. Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-581$350
   Table 5: World 10-Year Perspective for Antibacterial Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific (Inc. Japan), and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart).....II-591$350
   Table 6: World Recent Past, Current & Future Analysis for Cephalosporins by Geographic Region - US, Europe, Asia-Pacific (Inc. Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-601$350
   Table 7: World 10-Year Perspective for Cephalosporins by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific (Inc. Japan), and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart).....II-611$350
   Table 8: World Recent Past, Current & Future Analysis for Penicillins by Geographic Region - US, Europe, Asia-Pacific (Inc. Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-621$350
   Table 9: World 10-Year Perspective for Penicillins by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific (Inc. Japan), and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart).....II-631$350
   Table 10: World Recent Past, Current & Future Analysis for Fluoroquinolones by Geographic Region - US, Europe, Asia-Pacific (Inc. Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-641$350
   Table 11: World 10-Year Perspective for Fluoroquinolones by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart).....II-651$350
   Table 12: World Recent Past, Current & Future Analysis for Macrolides by Geographic Region - US, Europe, Asia-Pacific (Inc. Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-661$350
   Table 13: World 10-Year Perspective for Macrolides by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific (Inc. Japan), and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart).....II-671$350
   Table 14: World Recent Past, Current & Future Analysis for Other Anti-bacterial Drugs by Geographic Region - US, Europe, Asia-Pacific (Inc. Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-681$350
   Table 15: World 10-Year Perspective for Other Anti-bacterial Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific (Inc. Japan), and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart).....II-691$350
   A. Market Analysis.....III-1
Current & Future Analysis.....III-1
Products Approvals/Launches/Clinical Trials.....III-1
3$175
   Strategic Corporate Developments.....III-45$225
   Key Players.....III-94$175
   B. Market Analytics.....III-13
Table 16: US Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-13
1$200
   Table 17: US 10-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Dollar Sales for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-141$200
   A. Market Analysis.....III-15
Current and Future Analysis.....III-15
Strategic Corporate Developments.....III-15
3$175
   B. Market Analytics.....III-18
Table 18: European Recent Past, Current & Future Analysis for Antibacterial Drugs by Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-18
1$200
   Table 19: European 10-Year Perspective for Antibacterial Drugs by Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-191$200
   Table 20: European Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-201$200
   Table 21: European 10-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Dollar Sales for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-211$200
   A. Market Analysis.....III-22
Antibiotics Use Takes A Dip, As Regulatory Authorities’ Efforts Pays Off.....III-22
1$75
   B. Market Analytics.....III-23
Table 22: French Recent Past, Current & Future Analysis for Antibacterial Drugs- Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-23
1$200
   A. Market Analysis.....III-24
Key Player.....III-24
Bayer HealthCare AG.....III-24
1$75
   B. Market Analytics.....III-25
Table 23: German Recent Past, Current & Future Analysis for Antibacterial Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-25
1$200
   Market Analysis.....III-26
Table 24: Italian Recent Past, Current & Future Analysis for Antibacterial Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-26
1$200
   A. Market Analysis.....III-27
Infectious Diseases – A Quick Primer.....III-27
Research and Development of New Anti-Infectives.....III-27
Products Introduction.....III-27
1$75
   Strategic Corporate Development.....III-28
Key Players.....III-28
2$125
   B. Market Analytics.....III-30
Table 25: UK Recent Past, Current & Future Analysis for Antibacterial Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-30
1$200
   Market Analysis.....III-31
Table 26: Spanish Recent Past, Current & Future Analysis for Antibacterial Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-31
1$200
   A. Market Analysis.....III-32
Strategic Corporate Development.....III-32
Key Player.....III-32
F. Hoffmann-La Roche, Ltd. (Switzerland).....III-32
1$75
   B. Market Analytics.....III-33
Table 27: Rest of Europe Recent Past Current & Future Analysis for Antibacterial Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-33
1$200
   A. Market Analysis.....III-34
Focus on Select Regional Markets.....III-34
China.....III-34
Carbapenem Antibiotics Hold Great Potential.....III-34
India.....III-34
Injectable Antibiotics Demonstrate Robust Growth.....III-34
1$75
   New Initiative to Develop Novel Antibiotic Molecules.....III-35
Products Introductions/Developments.....III-35
1$75
   Strategic Corporate Developments.....III-362$125
   Key Players.....III-382$125
   B. Market Analytics.....III-40
Table 28: Asia-Pacific Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-40
1$200
   Table 29: Asia-Pacific 10-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Dollar Sales for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-411$200
   A. Market Analysis.....III-42
Strategic Corporate Developments.....III-42
1$75
   B. Market Analytics.....III-43
Table 30: Rest of World Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-43
1$200
   Table 31: Rest of World 10-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Dollar Sales for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Other Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-441$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com